VRCA - Verrica Pharmaceuticals Inc.

5.31
0.110   2.072%

Share volume: 71,433
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$5.20
0.11
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
11%
Profitability 0%
Dept financing 5%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.12%
1 Month
-23.15%
3 Months
-34.53%
6 Months
4.94%
1 Year
773.36%
2 Year
9.26%
Key data
Stock price
$5.31
P/E Ratio 
0.00
DAY RANGE
$5.09 - $5.35
EPS 
-$0.29
52 WEEK RANGE
$0.38 - $9.82
52 WEEK CHANGE
$733.59
MARKET CAP 
40.711 M
YIELD 
N/A
SHARES OUTSTANDING 
9.490 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
-0.21
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$93,966
AVERAGE 30 VOLUME 
$129,126
Company detail
CEO: Ted White
Region: US
Website: verrica.com
Employees: 40
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Verrica Pharmaceuticals Inc. develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; VP-103 for treating plantar warts.

Recent news